Literature DB >> 1513084

Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients.

J M Fernández1, M E Carbonell, N Mazzuchi, D Petruccelli.   

Abstract

The Cox stepwise logistic regression model was applied to analyze 22 factors potentially affecting morbidity and mortality (MM) in a cohort of 104 patients on chronic hemodialysis (CHD). Two groups of predictor variables were considered: patients' characteristics at the start of the study, and treatment-related factors recorded throughout the observation period. End points were either failure (death or admission to a hospital) or success. Patients were followed for 24 months. Thirty-nine patients were hospitalized and seven died in the interval. The two leading causes of failure were cardiovascular and infectious complications. Variables significantly associated with the result were: cardiac status (score greater than 2, beta = 1.16), mean predialysis blood pressure (greater than 115 mm Hg, beta = 0.94), total dialysis dose (greater than 0.90, beta = -0.59) and age (greater than 55 years, beta = 0.51). The probability of failure was 0.13 for patients who presented the four variables in the lowest risk class. This increased to a maximum of 0.60 with one risk factor, to 0.91 with two risk factors, and to 0.99 with three or more risk factors. We conclude that, given the conditions for this study, two treatment-related variables of CHD (mean predialysis blood pressure and total dialysis dose) are MM factors even when simultaneously analyzed with other well-established predictors (cardiac status and age). Mean arterial pressure (MAP) is the most important CHD treatment-related MM predictor.

Entities:  

Mesh:

Year:  1992        PMID: 1513084     DOI: 10.1038/ki.1992.156

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  6 in total

1.  Blood pressure and survival in long-term hemodialysis patients with and without polycystic kidney disease.

Authors:  Miklos Z Molnar; Lilia R Lukowsky; Elani Streja; Ramanath Dukkipati; Jennie Jing; Allen R Nissenson; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Hypertens       Date:  2010-12       Impact factor: 4.844

2.  Pharmacokinetics of aliskiren in patients with end-stage renal disease undergoing haemodialysis.

Authors:  Dmytro Khadzhynov; Torsten Slowinski; Ina Lieker; Hans-Hellmut Neumayer; Diego Albrecht; Henk Johan Streefkerk; Sam Rebello; Harm Peters
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

3.  Role of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the prevention of progression of renal disease.

Authors:  C V Ram; P Vergne-Marini
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

4.  A novel DSN-based fluorescence assay for MicroRNA-133a detection and its application for LVH diagnosis in maintenance hemodialysis patients.

Authors:  Pei Huang; Xuedan Guo; Yan Jin; Qing Huang
Journal:  J Clin Lab Anal       Date:  2020-07-16       Impact factor: 2.352

5.  Association of pre-transplant blood pressure with post-transplant outcomes.

Authors:  Miklos Z Molnar; Clarence E Foster; John J Sim; Adam Remport; Mahesh Krishnan; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Clin Transplant       Date:  2013-12-24       Impact factor: 2.863

6.  Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.

Authors:  Manfred Hecking; Marlies Antlanger; Wolfgang Winnicki; Thomas Reiter; Johannes Werzowa; Michael Haidinger; Thomas Weichhart; Hans-Dietrich Polaschegg; Peter Josten; Isabella Exner; Katharina Lorenz-Turnheim; Manfred Eigner; Gernot Paul; Renate Klauser-Braun; Walter H Hörl; Gere Sunder-Plassmann; Marcus D Säemann
Journal:  Trials       Date:  2012-06-08       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.